The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma

Bone Marrow Transplantation

Volumn 43, Issue 12, 2009, Pages 941-948

  Hoppe, B S ^a   Moskowitz, C H ^a   Zhang, Z ^a   Maragulia, J C ^a   Rice, R D ^a   Reiner, A S ^a   Hamlin, P A ^a   Zelenetz, A D ^a   Yahalom, J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW RESCUE; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INVOLVED FIELD RADIOTHERAPY; LARGE CELL LYMPHOMA; LIVER METASTASIS; LUNG EMBOLISM; LUNG INFECTION; LUNG INFILTRATE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION ENTEROPATHY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEPSIS; STEM CELL MOBILIZATION; SUPRAVENTRICULAR TACHYCARDIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 67649884048     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.408     Document Type: Article

References (32)

1. Barrington SF, Carr R. Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning. Clin Oncol (R Coll Radiol) 1995; 7: 334-335.
2. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325-329.
3. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
4. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 2004; 232: 823-829.
5. Schoder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42: 1139-1143.
6. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260-267.
7. Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30: 103-111.
8. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME et al Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003; 124: 608-613.
9. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110: 1361-1369.
10. Kasamon YL, Wahl RL, Swinnen LJ. FDG PET and high-dose therapy for aggressive lymphomas: Toward a risk-adapted strategy. Curr Opin Oncol 2004; 16: 100-105.
11. Schot B, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 2003; 123: 282-287.
12. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109: 486-491.
13. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al. Prognostic value of pretrans-plantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53-59.
14. Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 211-216.
15. Chadha M, Shank B, Fuks Z, Clarkson BD, Bonfiglio P, Gnecco C et al Improved survival of poor prognosis diffuse histiocytic (large cell) lymphoma managed with sequential induction chemotherapy, 'boost' radiation therapy, and autologous bone marrow transplantation. Int J Radiat Oncol Biol Phys 1988; 14: 407-415.
16. Hoppe BS, Moskowitz CH, Filippa DA, Moskowitz CS, Kewalramani T, Zelenet AD et al. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: Long-term disease control and toxicity. J Clin Oncol 2008; 26: 1858-1864.
17. Delbeke D, Rose D, Chapman W, Pinson C, Wright J, Beauchamp R et al Optimal interpretation of FDG-PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40: 1784-1791.
18. Tian J, Chen L, Wei B, Shao M, Ding Y, Yin D et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography in gastric malignancies. Nucl Med Commun 2004; 25: 825-831.
19. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
22. Cox D. Regression models and life-tables. J R Stat Soc 1972; 34 187-220.
23. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
24. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS et al. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4: 258-310.
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
26. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-1498.
27. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987; 316: 1499-1505.
28. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J 2005; 11: 425-431.
29. Oehler-Janne C, Taverna C, Stanek N, Negretti L, Lutolf UM, Ciernik IF. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: A case-control study. Hematol Oncol 2008; 26: 82-90.
30. Rapoport AP, Lifton R, Constine LS, Duerst RE, Abboud CN, Liesveld JL et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997; 19: 883-890.
31. Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience. Ann Oncol 2004; 15: 1504-1509.
32. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.